What is the fair value of Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) stock?

The current fair value estimate for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) is $243.80. This implies an estimated downside of 18.3% versus the current market price.

Is Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.3% versus the current market price.

What is the analyst price target for NASDAQ-LGND stock?

The available analyst price target for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) is $312.80. The analyst target implies estimated upside of 4.9%.

How is the financial health of Ligand Pharmaceuticals Incorporated?

The current financial health read for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Ligand Pharmaceuticals Incorporated's next earnings date?

The next earnings date currently listed for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) is August 11, 2026.

Does Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND)?

The current P/E ratio listed for Ligand Pharmaceuticals Incorporated (NASDAQ-LGND) is 38.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Ligand Pharmaceuticals Incorporated?

The current market capitalization listed for Ligand Pharmaceuticals Incorporated is 5.825 B.

What is the enterprise value of Ligand Pharmaceuticals Incorporated?

The current enterprise value listed for Ligand Pharmaceuticals Incorporated is 5.468 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Ligand Pharmaceuticals Incorporated?

The ticker symbol for Ligand Pharmaceuticals Incorporated is NASDAQ-LGND, and the stock is listed on NASDAQ.

What is the debt-to-total-capital ratio for Ligand Pharmaceuticals Incorporated?

The current debt-to-total-capital ratio listed for Ligand Pharmaceuticals Incorporated is 7.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Ligand Pharmaceuticals Incorporated?

The free float listed for Ligand Pharmaceuticals Incorporated is 97.4%. Free float helps investors understand how much of the share base is available for public trading.

Ligand Pharmaceuticals Incorporated (LGND) Fair Value & Stock...

Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets worldwide. Its portfolio includes products and programs across infectious disease, oncology, multiple myeloma, kidney disease, neurology, respiratory disease, rare disease, and other therapeutic areas. The company’s marketed and partnered products include Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, ZELSUVMI, EVOMELA, KYPROLIS, FILSPARI, PNEUMOSIL, QARZIBA, Teriparatide injection, RYLAZE, TZIELD, VAXNEUVANCE, Duavee, Frovatriptan, FYCOMPA, SESQUIENT, MEKINIST, Nexterone, VEKLURY, and Viviant. Ligand also has development programs such as ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, Lasofoxifene, Ensifentrine, QTORIN, Sparsentan, VK2809, ANEB-001, Reproxalap, VK0214, and VK5211. Incorporated in 1987, the company is based in Jupiter, Florida.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-LGND	$243.80	-18.3% Downside	Overvalued	$312.80	4.9% Upside	Fair	Great	—	—	—	0.0%	August 11, 2026	38.5x	5.9x	21.6x	5.825 B	5.468 B	7.2%	97.4%	8.5	—	80.1%